Skip to content
Life Sciences Series B Founded 2014

Eligo Bioscience

Developer of in vivo gene editing technology for microbiome modulation. The company offers a platform to edit the microbiome's gene repertoire. This platform aims to address diseases triggered or aggravated by specific bacterial genes. The technology targets the interactions between the microbiome and the host's immune system. Founded in 2014, headquartered in Paris, France. The company has raised $52.3M in funding…

📍 Paris, France · Genomics

Funding snapshot

Last roundSeries B
Amount$5M
Date13 May 2025
Total raised$52M
Team size47

About

Developer of in vivo gene editing technology for microbiome modulation. The company offers a platform to edit the microbiome's gene repertoire. This platform aims to address diseases triggered or aggravated by specific bacterial genes. The technology targets the interactions between the microbiome and the host's immune system. Founded in 2014, headquartered in Paris, France. The company has raised $52.3M in funding at the series b stage. The team comprises 47 (Jun 30, 2026) employees. Eligo Bioscience operates in the Genomics sector. The company focuses on Gene Editing. Notable investors include Sanofi Ventures, Bpifrance, Khosla Ventures, Seventure Partners, EIC Fund, Europa, among others. The company has a team of 47 employees.

Business model

Genomics > Enabling Technologies > Technology Platforms > Gene Editing

Team background

College Wise > Massachusetts Institute of Technology

Institutional investors

Sanofi Ventures Bpifrance Khosla Ventures Seventure Partners EIC Fund Europa NSG Ventures

Latest coverage

No articles yet.

Raising like Eligo Bioscience?

Analyze your pitch deck before your next raise.

Analyze My Deck →